| REVIEW ARTICLE |
|
| Year : 2012 | Volume
: 2
| Issue : 1 | Page : 3-7 |
|
|
An overview of angiogenesis and renal cell carcinoma
Shankhajit De1, Yadu Nandan Dey2, Piyali Sarkar1, Sudesh Gaidhani2
1 Vinayaka Missons Sikkim College of Pharmaceutical Sciences, Vinayaka Missons Sikkim University, Tadong, East Sikkim, India
2 Central Council for Research in Ayurveda and Siddha, Ministry of Health and Family Welfare, Government of India, Institutional Area, Janakpuri, New Delhi, India
Correspondence Address:
Yadu Nandan Dey
Central Council for Research in Ayurveda and Siddha, Ministry of Health and Family Welfare, Govt. of India, 61-65, Institutional Area, Janakpuri Opp. 'D' Block, New Delhi - 110 058
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2231-0738.93123
|
|
|
Renal cell carcinoma (RCC) is the most common malignant tumor of the kidney, and the incidence is increasing very rapidly across all population groups. Accumulation of hypoxia-induced factors and the over-expression of vascular endothelial growth factor (VEGF) are the most important predisposing factors for the progression of the disease. Angiogenesis facilitates tumor growth progression by supplying adequate oxygen and nutrition to the tumor cells through a series of interrelated steps. VEGF, Placental Growth Factor (PIGF), and Basic Fibroblast Growth Factor (bFGF) work together to increase angiogenesis in RCC. This review focuses on the possible targets in the treatment of the disease. Our literature review covers the last 15 years of reaseach related to this topic. We conclude that targeted therapies for RCC should be directed against specific molecules and signaling pathways and the therapy should be more selective for better tolerance. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
